As published by Wholesale Investor

The modern trajectory of biotechnology is rarely a straight line, but few arcs are as extraordinary as that of Professor Alan Trounson AO. In the late 1970s and 1980s, Trounson cemented his place in medical history as the co-pioneer of human IVF , creating the basic procedures used today, delivering many of the world’s IVF babies, before pioneering embryo freezing, embryo donation and other techniques; including the discovery of human embryonic stem cells a few years later. Having spent the first half of his career bringing life into the world, the emeritus Monash professor and former president of the $3 billion stem cell – California Institute for Regenerative Medicine is now pivoting to protect it.

“It is all driven by scientific inquiry and opportunistic translation,” says Trounson, now the CEO and executive chair of Melbourne-based Evinco Therapeutics Pty Ltd. For Trounson, the underlying thread has always been cell biology. Now, his sights are firmly set on defeating three of the most devastating neurological conditions of our time: Alzheimer’s disease, traumatic brain injury (TBI), and Parkinson’s disease.

Spinning out from Cartherics in December 2025, Evinco enters the market not as a speculative, one-shot drug developer, but as a sophisticated neurological platform. The company is currently securing a two-stage capital raise, beginning with a $2 million seed round designed to fund crucial proof-of-concept studies.

The “Cellular Mailbag” Breakthrough

To appreciate Evinco’s commercial value, one must look at a striking piece of clinical serendipity.

While working with natural killer (NK) cells—the immune system’s frontline soldiers typically deployed to destroy cancers—scientists observed a Korean company treat an Alzheimer’s patient with NK cells. The patient, silent for two years, dramatically regained speech and memory. Subsequent US Phase 2 studies revealed an astonishing 90% response rate, with 12 out of 13 patients showing stable or radically improved cognitive function.

But Trounson’s team noticed a critical biological blind spot: NK cells do not actually cross into the brain.

Instead, Evinco’s breakthrough centers on what these cells produce: extracellular vesicles. Think of these vesicles as “cellular mailbags” or biological nano-particles measuring a mere millionth of a millimeter. Because they are so microscopic, these vesicles easily bypass the notorious blood-brain barrier—a wall that blocks almost all cell therapies and large-molecule drugs.

By utilising these vesicles rather than living cells, Evinco has unlocked a non-invasive, home-delivery revolution. Delivered via a simple nasal spray, the vesicles migrate up the olfactory nerve directly into the brain. Because they can be freeze-dried and posted globally in a stable vial, they eliminate the need for expensive hospitalisation, complex cell manufacturing, or dangerous systemic toxicities.

Targeting a Multi-Trillion-Dollar “Blind Spot”

The prevailing Standard of Care in neurodegeneration is fundamentally broken. Current antibody therapies for Alzheimer’s are blockbuster commercial assets, yet clinically they achieve little more than slightly slowing the downward cognitive decline. They attempt to clear amyloid plaques while ignoring the raging fire underneath: neuroinflammation.

“If you address the inflammation that exists in these patients, it is likely you can address all components of the disease,” Trounson explains.

This shared biology is where Evinco’s platform logic shines. Neuroinflammation isn’t unique to Alzheimer’s; it is the destructive common denominator in Parkinson’s and TBI. When an athlete takes a hard hit to the head, or a child suffers a concussion, a cascade of neuroinflammation triggers within 24 hours, altering the exact same amyloid and other biomarkers seen in chronic dementia.

By treating neuroinflammation as a single target across three indications, Evinco mitigates traditional biotech binary risk. They are positioning a single platform technology to penetrate two colossal markets simultaneously: the 55 million people globally living with dementia, and the staggering $1.1 trillion annual global cost associated with traumatic brain injury and concussions.

Lean Operations and Big Pharma Validation

Evinco operates on a capital-efficient, highly strategic model. Rather than burning through hundreds of millions of dollars building bespoke manufacturing facilities, the company leverages existing infrastructure from global partners capable of expanding NK cells and harvesting their vesicles at a fraction of the cost.

“We know we can make hundreds of thousands of doses of this at a relatively low cost—in the tens of dollars, not hundreds of thousands of dollars,” notes Trounson.

This operational efficiency is paired with elite institutional credibility. Evinco has already attracted the attention of a major tier-one pharmaceutical company. This unnamed global pharma giant has already assisted Evinco in mapping its initial studies and is actively co-planning the upcoming preclinical roadmap—a massive external validation for an early-stage Australian startup.

The Value Inflection Point

For investors, the immediate timeline presents a classic asymmetric risk-reward profile. Evinco is currently conducting safety and efficacy studies in mice and domestic dogs suffering from canine cognitive dysfunction (canine Alzheimer’s).

The $2 million seed round serves as the launchpad for these proof-of-concept milestones. In the lifecycle of biotechnology, moving successfully through animal data and cementing a pre-clinical package alongside a major pharmaceutical partner represents the ultimate valuation rerate.

Once safety is definitively mirrored in these models, the pathway to human trials is uniquely lubricated due to the established safety profile of extracellular vesicles across global clinical literature. TBI, in particular, represents a rapid commercial wedge—offering a clear, non-invasive treatment where zero therapeutic options exist today for defense departments, professional sports leagues, and pediatric care.

The Investor Takeaway

Biotech investing is fundamentally about timing and team. In Professor Alan Trounson, investors are backing a leader who has spent a career successfully taking revolutionary science from the laboratory bench to the commercial bedside.

Compared to Nasdaq-listed peers chasing single-antibody treatments for Alzheimer’s at multi-billion-dollar valuations, Evinco’s platform approach offers multiple shots on goal at a ground-floor entry price. With big pharma validation already in the mix and a universal nasal spray that reduces manufacturing costs to double digits, Evinco is firmly sitting in the investor “hot zone” for 2026.